A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals [clinicaltrials:NCT02242656]

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals [clinicaltrials:NCT02242656]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
http://bio2rdf.org/clinicaltrials:NCT02242656

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals [clinicaltrials:NCT02242656]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
http://bio2rdf.org/clinicaltrials:NCT02242656
Bio2RDF identifier
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT02242656
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
MP-101 will be evaluate ...... rience bowel movements.
brief title [clinicaltrials_vocabulary:brief-title]
A Phase III Study to Evaluate ...... te Response to Anti-Diarrheals
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Phase 3, Open Label Responde ...... te Response to Anti-Diarrheals
org study id [clinicaltrials_vocabulary:org-study-id]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
why stopped [clinicaltrials_vocabulary:why-stopped]
Transfer of IND to new marketing authorization holder
identifier
clinicaltrials:NCT02242656
title
A Phase III Study to Evaluate ...... te Response to Anti-Diarrheals
@en
inDataset
type
label
A Phase III Study to Evaluate ...... s [clinicaltrials:NCT02242656]
@en